[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
November 1, 1952


Author Affiliations

Medical Research Council, Dental Research Unit, King's College Hospital Medical School London, S.E.5., England

JAMA. 1952;150(9):951. doi:10.1001/jama.1952.03680090115023

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


To the Editor:  —It has been shown that diphenylhydantoin affects the adrenal glands of certain laboratory animals (Staple, P. H.: Lancet1:1074, 1951; Woodbury, D. M.: J. Pharmacol. & Exper. Therap.105:46, 1952). In man diphenylhydantoin sodium (dilantin sodium®) may produce hirsutism, and there is some evidence (Staple, P. H.: Lancet1:372, 1952) that its anticonvulsant action may be modified by salicylates, which apparently stimulate adrenocortical activity. It would appear then that the results of Costa and Bonnycastle (J. A. M. A.149:1093 [July 19] 1952) include an effect due to diphenylhydantoin sodium as well as that due to epilepsy per se, since they state that their patients continued to receive their usual medication throughout the investigations.

First Page Preview View Large
First page PDF preview
First page PDF preview